2′-Fucosyllactose and 3-Fucosyllactose Alleviates Interleukin-6-Induced Barrier Dysfunction and Dextran Sodium Sulfate-Induced Colitis by Improving Intestinal Barrier Function and Modulating the Intestinal Microbiome
Ulcerative colitis is an inflammatory bowel disease (IBD) with relapsing and remitting patterns, and it is caused by varied factors, such as the intestinal inflammation extent and duration. We examined the preventative effects of human milk oligosaccharides (HMOs) on epithelial barrier integrity and...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-04-01
|
Series: | Nutrients |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6643/15/8/1845 |
_version_ | 1797604041790849024 |
---|---|
author | Yeon-Ji Kim Han-Hae Kim Chul-Soo Shin Jong-Won Yoon Seon-Min Jeon Young-Ha Song Kwang-Youn Kim Kyungho Kim |
author_facet | Yeon-Ji Kim Han-Hae Kim Chul-Soo Shin Jong-Won Yoon Seon-Min Jeon Young-Ha Song Kwang-Youn Kim Kyungho Kim |
author_sort | Yeon-Ji Kim |
collection | DOAJ |
description | Ulcerative colitis is an inflammatory bowel disease (IBD) with relapsing and remitting patterns, and it is caused by varied factors, such as the intestinal inflammation extent and duration. We examined the preventative effects of human milk oligosaccharides (HMOs) on epithelial barrier integrity and intestinal inflammation in an interleukin (IL)-6-induced cell model and dextran sodium sulfate (DSS)-induced acute mouse colitis model. HMOs including 2′-fucosyllactose (FL) and 3-FL and positive controls including fructooligosaccharide (FOS) and 5-acetylsalicylic acid (5-ASA) were orally administrated once per day to C57BL/6J mice with colitis induced by 5% DSS in the administered drinking water. 2′-FL and 3-FL did not affect the cell viability in Caco-2 cells. Meanwhile, these agents reversed IL-6-reduced intestinal barrier function in Caco-2 cells. Furthermore, 2′-FL and 3-FL reversed the body weight loss and the remarkably short colon lengths in DSS-induced acute colitis mice. Moreover, 2′-FL and 3-FL obviously protected the decreasing expression of zonula occluden-1 and occludin in colon tissue relative to the findings in the DSS-treated control group. 2′-FL and 3-FL significantly reduced IL-6 and tumor necrosis factor-α levels in serum relative to the control findings. The summary of these results shows that HMOs prevent colitis mainly by enhancing intestinal barrier function and advancing anti-inflammatory responses. Therefore, HMOs might suppress inflammatory responses and represent candidate treatments for IBD that protect intestinal integrity. |
first_indexed | 2024-03-11T04:40:34Z |
format | Article |
id | doaj.art-a2187367003645fca138a2f1619be442 |
institution | Directory Open Access Journal |
issn | 2072-6643 |
language | English |
last_indexed | 2024-03-11T04:40:34Z |
publishDate | 2023-04-01 |
publisher | MDPI AG |
record_format | Article |
series | Nutrients |
spelling | doaj.art-a2187367003645fca138a2f1619be4422023-11-17T20:45:17ZengMDPI AGNutrients2072-66432023-04-01158184510.3390/nu150818452′-Fucosyllactose and 3-Fucosyllactose Alleviates Interleukin-6-Induced Barrier Dysfunction and Dextran Sodium Sulfate-Induced Colitis by Improving Intestinal Barrier Function and Modulating the Intestinal MicrobiomeYeon-Ji Kim0Han-Hae Kim1Chul-Soo Shin2Jong-Won Yoon3Seon-Min Jeon4Young-Ha Song5Kwang-Youn Kim6Kyungho Kim7Korean Medicine (KM)—Application Center, Korea Institute of Oriental Medicine (KIOM), Daegu 41062, Republic of KoreaKorean Medicine (KM)—Application Center, Korea Institute of Oriental Medicine (KIOM), Daegu 41062, Republic of KoreaAdvanced Protein Technologies Corp., Suwon 16229, Republic of KoreaAdvanced Protein Technologies Corp., Suwon 16229, Republic of KoreaAdvanced Protein Technologies Corp., Suwon 16229, Republic of KoreaAdvanced Protein Technologies Corp., Suwon 16229, Republic of KoreaKorean Medicine (KM)—Application Center, Korea Institute of Oriental Medicine (KIOM), Daegu 41062, Republic of KoreaKorean Medicine (KM)—Application Center, Korea Institute of Oriental Medicine (KIOM), Daegu 41062, Republic of KoreaUlcerative colitis is an inflammatory bowel disease (IBD) with relapsing and remitting patterns, and it is caused by varied factors, such as the intestinal inflammation extent and duration. We examined the preventative effects of human milk oligosaccharides (HMOs) on epithelial barrier integrity and intestinal inflammation in an interleukin (IL)-6-induced cell model and dextran sodium sulfate (DSS)-induced acute mouse colitis model. HMOs including 2′-fucosyllactose (FL) and 3-FL and positive controls including fructooligosaccharide (FOS) and 5-acetylsalicylic acid (5-ASA) were orally administrated once per day to C57BL/6J mice with colitis induced by 5% DSS in the administered drinking water. 2′-FL and 3-FL did not affect the cell viability in Caco-2 cells. Meanwhile, these agents reversed IL-6-reduced intestinal barrier function in Caco-2 cells. Furthermore, 2′-FL and 3-FL reversed the body weight loss and the remarkably short colon lengths in DSS-induced acute colitis mice. Moreover, 2′-FL and 3-FL obviously protected the decreasing expression of zonula occluden-1 and occludin in colon tissue relative to the findings in the DSS-treated control group. 2′-FL and 3-FL significantly reduced IL-6 and tumor necrosis factor-α levels in serum relative to the control findings. The summary of these results shows that HMOs prevent colitis mainly by enhancing intestinal barrier function and advancing anti-inflammatory responses. Therefore, HMOs might suppress inflammatory responses and represent candidate treatments for IBD that protect intestinal integrity.https://www.mdpi.com/2072-6643/15/8/18452′-fucosyllactose3-fucosyllactoseinflammationtight junctionulcerative colitis |
spellingShingle | Yeon-Ji Kim Han-Hae Kim Chul-Soo Shin Jong-Won Yoon Seon-Min Jeon Young-Ha Song Kwang-Youn Kim Kyungho Kim 2′-Fucosyllactose and 3-Fucosyllactose Alleviates Interleukin-6-Induced Barrier Dysfunction and Dextran Sodium Sulfate-Induced Colitis by Improving Intestinal Barrier Function and Modulating the Intestinal Microbiome Nutrients 2′-fucosyllactose 3-fucosyllactose inflammation tight junction ulcerative colitis |
title | 2′-Fucosyllactose and 3-Fucosyllactose Alleviates Interleukin-6-Induced Barrier Dysfunction and Dextran Sodium Sulfate-Induced Colitis by Improving Intestinal Barrier Function and Modulating the Intestinal Microbiome |
title_full | 2′-Fucosyllactose and 3-Fucosyllactose Alleviates Interleukin-6-Induced Barrier Dysfunction and Dextran Sodium Sulfate-Induced Colitis by Improving Intestinal Barrier Function and Modulating the Intestinal Microbiome |
title_fullStr | 2′-Fucosyllactose and 3-Fucosyllactose Alleviates Interleukin-6-Induced Barrier Dysfunction and Dextran Sodium Sulfate-Induced Colitis by Improving Intestinal Barrier Function and Modulating the Intestinal Microbiome |
title_full_unstemmed | 2′-Fucosyllactose and 3-Fucosyllactose Alleviates Interleukin-6-Induced Barrier Dysfunction and Dextran Sodium Sulfate-Induced Colitis by Improving Intestinal Barrier Function and Modulating the Intestinal Microbiome |
title_short | 2′-Fucosyllactose and 3-Fucosyllactose Alleviates Interleukin-6-Induced Barrier Dysfunction and Dextran Sodium Sulfate-Induced Colitis by Improving Intestinal Barrier Function and Modulating the Intestinal Microbiome |
title_sort | 2 fucosyllactose and 3 fucosyllactose alleviates interleukin 6 induced barrier dysfunction and dextran sodium sulfate induced colitis by improving intestinal barrier function and modulating the intestinal microbiome |
topic | 2′-fucosyllactose 3-fucosyllactose inflammation tight junction ulcerative colitis |
url | https://www.mdpi.com/2072-6643/15/8/1845 |
work_keys_str_mv | AT yeonjikim 2fucosyllactoseand3fucosyllactosealleviatesinterleukin6inducedbarrierdysfunctionanddextransodiumsulfateinducedcolitisbyimprovingintestinalbarrierfunctionandmodulatingtheintestinalmicrobiome AT hanhaekim 2fucosyllactoseand3fucosyllactosealleviatesinterleukin6inducedbarrierdysfunctionanddextransodiumsulfateinducedcolitisbyimprovingintestinalbarrierfunctionandmodulatingtheintestinalmicrobiome AT chulsooshin 2fucosyllactoseand3fucosyllactosealleviatesinterleukin6inducedbarrierdysfunctionanddextransodiumsulfateinducedcolitisbyimprovingintestinalbarrierfunctionandmodulatingtheintestinalmicrobiome AT jongwonyoon 2fucosyllactoseand3fucosyllactosealleviatesinterleukin6inducedbarrierdysfunctionanddextransodiumsulfateinducedcolitisbyimprovingintestinalbarrierfunctionandmodulatingtheintestinalmicrobiome AT seonminjeon 2fucosyllactoseand3fucosyllactosealleviatesinterleukin6inducedbarrierdysfunctionanddextransodiumsulfateinducedcolitisbyimprovingintestinalbarrierfunctionandmodulatingtheintestinalmicrobiome AT younghasong 2fucosyllactoseand3fucosyllactosealleviatesinterleukin6inducedbarrierdysfunctionanddextransodiumsulfateinducedcolitisbyimprovingintestinalbarrierfunctionandmodulatingtheintestinalmicrobiome AT kwangyounkim 2fucosyllactoseand3fucosyllactosealleviatesinterleukin6inducedbarrierdysfunctionanddextransodiumsulfateinducedcolitisbyimprovingintestinalbarrierfunctionandmodulatingtheintestinalmicrobiome AT kyunghokim 2fucosyllactoseand3fucosyllactosealleviatesinterleukin6inducedbarrierdysfunctionanddextransodiumsulfateinducedcolitisbyimprovingintestinalbarrierfunctionandmodulatingtheintestinalmicrobiome |